Saghmos Therapeutics to Present at the 25th BioCentury Future Leaders Conference in New York

NEW YORK--()--Saghmos Therapeutics, Inc., a privately held biopharmaceutical company whose mission is to prevent and treat kidney injury due to contrast dyes, today announced that it will present at the 25th BioCentury Future Leaders conference New York City.

Anna Kazanchyan, M.D., Chief Executive Officer and Chairwoman of Saghmos, will provide an overview of the company and its lead program, ST-62516, which is positioned to enter Phase 3 development to improve cardiorenal outcomes in patients undergoing percutaneous coronary intervention (PCI). The presentation is scheduled for Friday, March 23, 2018, at 2pm EDT in Room 402/403 at the Millennium Broadway Hotel & Conference Center in New York, NY.

About Saghmos Therapeutics
Saghmos Therapeutics is a privately held biopharmaceutical company whose mission is to prevent and treat kidney injury due to contrast dyes. Saghmos’ lead program, ST-62516 is positioned to enter Phase 3 development for reduction of major adverse renal and cardiac events (MARCE) associated with contrast-induced acute kidney injury (CI-AKI) in patients undergoing percutaneous coronary intervention (PCI). CI-AKI is a silent killer, leading to heart attacks, prolonged hospitalization, need for dialysis and death. It is a multi-billion dollar market opportunity, with no FDA-approved drugs for prevention or treatment.

Contacts

Saghmos Therapeutics
Anna Kazanchyan, M.D., +1 203-388-9977
CEO & Chairwoman
anna@saghmos.com
or
LaVoieHealthScience
Beth Kurth, +1 617-374-8800, Ext. 106
bkurth@lavoiehealthscience.com

Recent Stories

RSS feed for Saghmos Therapeutics, Inc.

Release Summary

Saghmos Therapeutics, a biopharmaceutical company treating kidney injury will present at BioCentury Future Leaders in New York City Friday March 23.